Expanding the frontier of cancer immunotherapy
Our proprietary technology platform is designed to discover antibodies that recognize intracellular protein fragments via the MHC-peptide complex, leading the way for immunotherapy against a previously inaccessible world of potential targets. These antibodies can effectively reach inside a cancer cell to recognize cancer-associated proteins and then mobilize the immune system to attack.
As proteins inside the cell get broken down during normal cellular functions, fragments of these proteins (peptides) are carried to the cell surface by MHC (major histocompatibility complex) molecules. When T cells (a key component of the immune system) recognize these fragments as abnormal, they kill the diseased cell.